Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Severe Acute Respiratory-Syndrome Treatment Market Grown from 2024 to 2025?
The market size for the treatment of severe acute respiratory syndrome has experienced significant expansion in recent years. The market value is projected to increase from $3.45 billion in 2024 to $3.97 billion in 2025 with a compound annual growth rate (CAGR) of 15.2%. The growth witnessed during the historic period is credited to factors such as the global response to outbreaks, development of antiviral drugs and vaccines, and better preparation for public health emergencies.
What Growth Rate Is Anticipated for the Severe Acute Respiratory-Syndrome Treatment Market in the Coming Years?
Anticipations are high for the severe acute respiratory-syndrome treatment market as it is projected to expand considerably in the upcoming years, reaching an estimated value of $7.15 billion by 2029. This projection mirrors a robust compound annual growth rate (CAGR) of 15.8%. Factors contributing to this promising growth during the forecast period are broad-spectrum antivirals, new therapeutics, advancement in vaccines, and pandemic preparedness. Significant trends to watch for during this period include therapies targeting rna, the role of ai in drug discovery, worldwide collaborations, and public health education initiatives.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp
Who Are the Leading Companies in the Severe Acute Respiratory-Syndrome Treatment Market?
Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.
What Are the Key Drivers of the Severe Acute Respiratory-Syndrome Treatment Market?
The increase in respiratory disease cases is anticipated to fuel the growth of the severe acute respiratory syndrome treatment market. Respiratory diseases encompass a range of health conditions impacting the respiratory system, which regulates breathing and the exchange of gases between the body and the environment. Severe acute respiratory syndrome treatments are utilized in managing these diseases to mitigate symptoms, avert respiratory failure, decrease inflammation, and sustain oxygen levels. The National Asthma Council, an Australian non-profit organization for elevating asthma care, recorded 467 asthma-related deaths in November 2023. The figure, consisting of 299 women and 168 men, marked an increase from the 355 deaths in 2021. Consequently, the escalating prevalence of respiratory diseases is stimulating the substantial growth of the severe acute respiratory syndrome treatment market. The severe acute respiratory syndrome treatment market is also expected to be bolstered by the surge in research and development investments. These investments entail organizations, governments, or entities channeling financial and human resources into structured and creative research to gain new insights. Heightened investments in research and development are instrumental in enhancing treatments for severe respiratory conditions like SARS and COVID-19. They facilitate the creation of effective drugs, vaccines, diagnostic tools, and therapeutic strategies for better patient outcomes and global health readiness. In August 2023, the U.S. Department of Health and Human Services reported more than $1.4 billion given to Project NextGen by the Administration for Strategic Preparedness and Response. This fund supports the development of advanced COVID-19 vaccines and therapies. Therefore, the surge in research and development investments is greatly contributing to the growth of the severe acute respiratory syndrome treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13027&type=smp
What Are the Key Market Segments in the Severe Acute Respiratory-Syndrome Treatment Industry?
The severe acute respiratory-syndrome treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS‑CoV‑2)
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs, Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators, Supportive Medications
What Are the Latest Trends in the Severe Acute Respiratory-Syndrome Treatment Market?
Leading firms in the severe acute respiratory syndrome treatment market are pioneering unique methods such as multiplexed real-time PCR to maintain their competitive edge in the sector. Multiplexed real-time PCR is a method in molecular biology that enables multiple DNA or RNA targets to be amplified and identified in one single process. As an example, in July 2022, TransGen Biotech Co. Ltd., a Beijing-based firm specializing in molecular and cellular biology products, unveiled the Trans-SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus Assay. This next-generation assay is a multiplexed real-time PCR (polymerase chain reaction) assay capable of identifying and distinguishing severe acute respiratory syndrome COVID-19 2 (SARS CoV 2), Influenza A, Influenza B, and respiratory syncytial virus (RSV) within a single sample. It acts as a crucial instrument in diagnosing and treating SARS, influenza, and RSV, thereby aiding in formulating treatment strategies and controlling the spread of these diseases.
Access The Full Report Here:
What Are the Key Regional Markets in the Severe Acute Respiratory-Syndrome Treatment Industry?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13027
This Report Delivers Insight On:
1. How big is the severe acute respiratory-syndrome treatment market, and how is it changing globally?
2. Who are the major companies in the severe acute respiratory-syndrome treatment market, and how are they performing?
3. What are the key opportunities and risks in the severe acute respiratory-syndrome treatment market right now?
4. Which products or customer segments are growing the most in the severe acute respiratory-syndrome treatment market?
5. What factors are helping or slowing down the growth of the severe acute respiratory-syndrome treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model